GILD Gilead Sciences
Updated
Nasdaq 100 CompaniesS&P 500 Companies
Healthcare · Biological Products, (No Diagnostic Substances)
Gilead Sciences (GILD) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $187.5 billion. Shares last traded at $151.21, 3.9% below their 52-week high. Over the past year the stock is up 33.8%. Net profit margin is -10.6%, below the peer median of 5.3%. Revenue grew 2.4% year over year. The shares yield 2.1% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
GILD Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $4.00B | $3.19 | 47% |
| 2024-12-31 | $3.92B | $3.12 | 816% |
| 2023-12-31 | $3.81B | $3.03 | 67% |
| 2022-12-31 | $3.71B | $2.94 | 81% |
| 2021-12-31 | $3.60B | $2.86 | 58% |
| 2020-12-31 | $3.45B | $2.73 | 2804% |
| 2019-12-31 | $3.22B | $2.52 | 60% |
| 2018-12-31 | $2.97B | $2.27 | 54% |
| 2017-12-31 | $2.73B | $2.07 | 59% |
| 2016-12-31 | $2.46B | $1.81 | 18% |
| 2015-12-31 | $1.87B | $1.23 | 10% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-6.82 | 2026-08-06 |
| Q1 2026 | $1.61 | 2026-05-07 |
| FY 2025 | $6.78 | 2026-02-24 |
| Q3 2025 | $5.04 | 2025-11-07 |
| Q2 2026 | $2.61 | 2026-08-06 |
| Q1 2026 | $1.04 | 2026-05-07 |
Biological Products, (No Diagnostic Substances) peers
GILD vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| MRNA | Moderna | $58.8B | -18.68 | — | — | -1.94% |
| RVMD | Revolution Medicines, Inc. | $45.2B | -25.55 | — | — | +0.76% |
| BIIB | Biogen | $33.1B | 24.16 | 3.34 | 13.8% | +0.78% |
| NBIX | Neurocrine Biosciences Inc | $16.1B | 22.81 | 4.77 | 20.9% | +0.33% |
| EXEL | Exelixis, Inc. | $14.7B | 17.03 | 6.02 | 35.3% | +1.00% |
| HALO | Halozyme Therapeutics, Inc. | $12.6B | 30.39 | 7.55 | 24.9% | +1.01% |
| TECH | Bio-Techne | $11.4B | 62.48 | 9.35 | 15.0% | +0.21% |
| KRYS | Krystal Biotech, Inc. | $11.0B | 45.52 | 24.95 | 54.8% | +0.58% |
| APGE | Apogee Therapeutics, Inc. | $10.2B | -34.57 | — | — | +0.04% |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | -32.51 | — | — | -1.24% |
| RGEN | Repligen Corp | $9.6B | 230.53 | 12.20 | 5.3% | -1.87% |
| PCVX | Vaxcyte, Inc. | $9.1B | -8.56 | — | — | -0.62% |
🇨🇦 Gilead Sciences also trades on Cboe Canada as a CAD-hedged Canadian Depositary Receipt (CDR) under GILD. A CDR represents the same underlying GILD shares in Canadian dollars with the currency exposure hedged; this page tracks the US-listed shares.
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.